Sucampo Pharmaceuticals Announces Presentation at Deutsche Bank’s 25th Annual Leveraged Finance Conference
27 Septiembre 2017 - 7:43PM
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global
biopharmaceutical company, today announced that the company will
participate in Deutsche Bank’s 25th Annual Leveraged Finance
Conference on Wednesday, October 4th at 2:15PM Mountain.
Investors interested in arranging a meeting with the Company's
management during this conference should contact the conference
coordinator.
About Sucampo Pharmaceuticals,
Inc.
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company
focused on the development and commercialization of highly
specialized medicines. Sucampo has a late-stage pipeline of product
candidates in clinical development for orphan disease areas,
including VTS-270, a mixture of 2-hydroxypropyl-B-cyclodextrins
with a specific compositional fingerprint that has been granted
orphan designation in the U.S. and Europe and is in a pivotal Phase
2/3 clinical trial for the treatment of Niemann-Pick Disease Type
C-1, a rare progressive genetic disorder. VTS-270 has also
been granted breakthrough therapy designation in the U.S.
Sucampo has an exclusive option for the North American rights to
CPP-1X/sulindac, which is in Phase 3 development for the treatment
of familial adenomatous polyposis and has been granted orphan drug
designation in the U.S. The company has two marketed products –
AMITIZA and RESCULA. For more information, please visit
www.sucampo.com.
The Sucampo logo and the tagline, The Science of
Innovation, are registered trademarks of Sucampo AG. AMITIZA is a
registered trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow
us on LinkedIn (Sucampo Pharmaceuticals).
Twitter LinkedIn
Contact:Sucampo Pharmaceuticals, Inc.Silvia
TaylorSenior Vice President, Investor Relations and Corporate
Affairs1-240-223-3718staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Gráfica de Acción Histórica
De May 2023 a May 2024
Real-Time news about Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ): 0 recent articles
Más de Artículos de Noticias